Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Seers (458870.KQ)
Pyeongtaek-si, KR
Seers Technology Co., Ltd. specializes in delivering remote healthcare solutions, particularly those involving patient surveillance. The company's diverse product range features wearable biosensors, comprehensive central patient monitoring systems, medical artificial intelligence (AI) applications, and specialized medical adhesive materials. Young-Shin Lee established this enterprise on August 11, 2009, and its corporate headquarters are located in Pyeongtaek-si, South Korea.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.79% | -17.96% | -33.37% | -31.67% | -29.44% | -22.50% | +401.58% | +414.86% | +414.86% | +414.86% | +414.86% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 2 | +1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Specialties: +8.3%+494.7% ★ Q1'26: +699.6% (vs Q1'25)
-
EPS growth Medical - Specialties: +10.1%+269.8% ★ Q1'26: +2,406.6% (vs Q1'25)
-
FCF margin FCF growth · Medical - Specialties: +51.3%-2.6% Q1'26: +11.1% (vs Q1'25)
-
EBIT margin Medical - Specialties: +12.6%+33.9% ★ Q1'26: +42.6% (vs Q1'25)
-
ROIC Medical - Specialties: +6.6%+50.5% ★ Q1'26: +127.1% (vs Q1'25)
-
Share dilution Medical - Specialties: 0.0%+7.4% Q1'26: +0.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Specialties: -0.39×0.22× ★ Q1'26: 0.07× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 5 Rev. Ana. 3 EPS Ana. |
Dec 2027 5 Rev. Ana. 4 EPS Ana. |
Dec 2028 1 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
8.10B
est: 7.50B (+8.0%)
|
48.17B
est: 48.16B (+0.0%)
|
138.29B
118.89B – 171.81B
+187.1% YoY
|
196.54B
168.84B – 266.08B
+42.1% YoY
|
258.50B
222.14B – 337.64B
+31.5% YoY
|
| EBITDA |
-7.26B
est: -5.30B (-37.1%)
|
17.64B
est: -34.01B (+151.9%)
|
-97.65B
-121.32B – -83.95B
-187.1% YoY
|
-138.78B
-187.88B – -119.22B
-42.1% YoY
|
-182.53B
-238.42B – -156.86B
-31.5% YoY
|
| EBIT |
-8.39B
est: -5.49B (-52.7%)
|
16.33B
est: -35.26B (+146.3%)
|
-101.26B
-125.80B – -87.05B
-187.1% YoY
|
-143.91B
-194.82B – -123.63B
-42.1% YoY
|
-189.28B
-247.22B – -162.65B
-31.5% YoY
|
| Net Income |
-8.87B
est: -2.96B (-199.3%)
|
16.18B
est: 16.43B (-1.5%)
|
58.30B
50.82B – 72.00B
+254.9% YoY
|
75.25B
65.00B – 85.74B
+29.1% YoY
|
107.97B
88.23B – 150.94B
+43.5% YoY
|
| SGA |
4.05B
est: 10.91B (-62.9%)
|
—
est: 70.03B (-100.0%)
|
201.09B
172.88B – 249.83B
+187.1% YoY
|
285.79B
245.51B – 386.91B
+42.1% YoY
|
375.89B
323.02B – 490.97B
+31.5% YoY
|
| EPS |
-250.81
est: -78.00 (-221.6%)
|
425.92
est: 432.39 (-1.5%)
|
1,534.33
1,337.56 – 1,894.95
+254.9% YoY
|
1,980.33
1,710.54 – 2,256.49
+29.1% YoY
|
2,841.50
2,321.90 – 3,972.42
+43.5% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-28 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-27 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-26 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-22 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-21 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-20 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-19 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-18 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-15 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-14 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-13 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-12 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-11 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-08 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-07 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-04 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-29 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-15 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-14 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Dae-yeop Kang | CSO | — | — |
| Gyu-Seok Bang | COO | — | — |
| Hee-Seok Song | CTO | — | — |
| Seong-Jong Kim | CBO | — | — |
| Young-Shin Lee | Founder, CEO & Executive Director | — | male |
| Young-Tae Jang | CFO | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 458870.KQ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
